UCB courts JPM investors with growth projections

15 January 2025

Belgian drugmaker UCB (Euronext: UCB) has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at the 43rd JP Morgan (JPM) Healthcare Conference in San Francisco, USA.

The company, which has a focus on developing solutions in immunology and neurology, has now predicted a decade-plus of growth.

Jean-Christophe Tellier, chief executive of UCB, said: “At UCB, we are looking ahead with confidence and determination. We will continue to deliver differentiated innovation, transforming what is possible for patients, caregivers, medical professionals and shareholders. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical